MAPK1 and liver dysplastic nodule: Ultimately, ten genes AKT1, PPARG, PTGS2, EGFR, ESR1, JAK2, MAPK1, PARP1, GSK3B, PPARA were found to be the primary therapeutic targets of Crateva’s activities against DN.